FTSE 100 Index Ends 0.37% Lower at 7374.83 — Data Talk
The FTSE 100 Index is down 27.31 points or 0.37% today to 7374.83
--Down for four consecutive trading days
--Down 300.38 points or 3.91% over the last four trading days
--Largest four day point and percentage decline since Thursday, March 16, 2023
--Longest losing streak since Monday, Aug. 21, 2023, when the market fell for seven straight trading days
--Off 7.98% from its record close of 8014.31 hit Monday, Feb. 20, 2023
--Up 16.36% since the pre-Brexit vote level of 6338.10 hit Thursday, June 23, 2016
--Lowest closing value since Friday, Aug. 25, 2023
--Off 7.98% from its 52-week high of 8014.31 hit Monday, Feb. 20, 2023
--Up 5.15% from its 52-week low of 7013.48 hit Tuesday, Oct. 25, 2022
--Rose 5.14% from 52 weeks ago
--Off 7.98% from its 2023 closing high of 8014.31 hit Monday, Feb. 20, 2023
--Up 1.62% from its 2023 closing low of 7256.94 hit Friday, July 7, 2023
--Month-to-date it is down 3.07%
--Year-to-date it is down 76.91 points or 1.03%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 23, 2023 12:37 ET (16:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track